Information for Investors

We believe providing an individualized risk of spontaneous premature birth and other pregnancy complications is a critical first step to improving maternal and newborn health. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to meaningfully reduce healthcare costs. 

Corporate Presentation
Relevant Publications

Find the latest publications here.

Recent News
Jul 9, 2024

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics...

Jul 1, 2024

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

May 28, 2024

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

View More

Upcoming Events
Wednesday, May 8, 2024
5:00pm - 6:00pm EDT

View Past Events

Email Alerts

Sign up for our investor relations email list here.